These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 28926510)
41. Microablative fractional CO Pitsouni E; Grigoriadis T; Falagas M; Tsiveleka A; Salvatore S; Athanasiou S Lasers Med Sci; 2017 Nov; 32(8):1865-1872. PubMed ID: 28770400 [TBL] [Abstract][Full Text] [Related]
42. Low genitourinary tract risks in women living with the human immunodeficiency virus. Pérez-López FR; Fernández-Alonso AM; Mezones-Holguín E; Vieira-Baptista P Climacteric; 2023 Aug; 26(4):316-322. PubMed ID: 37054721 [TBL] [Abstract][Full Text] [Related]
43. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Nappi RE; Palacios S; Panay N; Particco M; Krychman ML Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Archer DF Menopause; 2010; 17(1):194-203. PubMed ID: 19602990 [TBL] [Abstract][Full Text] [Related]
45. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974 [TBL] [Abstract][Full Text] [Related]
46. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. North American Menopause Society Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512 [TBL] [Abstract][Full Text] [Related]
48. Vaginal Health During Breast Cancer Treatment. Falk SJ; Bober S Curr Oncol Rep; 2016 May; 18(5):32. PubMed ID: 27074843 [TBL] [Abstract][Full Text] [Related]
54. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Simon JA; Kokot-Kierepa M; Goldstein J; Nappi RE Menopause; 2013 Oct; 20(10):1043-8. PubMed ID: 23571518 [TBL] [Abstract][Full Text] [Related]
55. Vaginal estrogens for the treatment of dyspareunia. Krychman ML J Sex Med; 2011 Mar; 8(3):666-74. PubMed ID: 21091878 [TBL] [Abstract][Full Text] [Related]
56. Vaginal estrogen use and effects on quality of life and urogenital morbidity in postmenopausal women after publication of the Women's Health Initiative in New York City. Setty P; Rekedal L; Warren MP Menopause; 2016 Jan; 23(1):7-10. PubMed ID: 26263282 [TBL] [Abstract][Full Text] [Related]
57. Relationship between delivery modes and genitourinary syndrome among postmenopausal women. Yaralizadeh M; Abedi P; Salehinejad P Climacteric; 2017 Aug; 20(4):362-366. PubMed ID: 28440666 [TBL] [Abstract][Full Text] [Related]
58. Management of dyspareunia in postmenopausal women. Wallis LA J Am Med Womens Assoc (1972); 1987; 42(3):82-4. PubMed ID: 3584783 [No Abstract] [Full Text] [Related]
60. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Domoney C; Currie H; Panay N; Maamari R; Nappi RE Menopause Int; 2013 Jun; 19(2):69-76. PubMed ID: 23778561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]